Chairman and Chief Executive Officer, Eloxx Pharmaceuticals
Mr. Robert (Bob) E. Ward is the Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. (“Eloxx”). He previously served as the Chief Executive Officer and President at Radius Health, Inc., successfully completing the initial public offering that became the top performing IPO in 2014; raised over $780M from private and public sources; achieved FDA approval and launch of the new drug TYMLOS™ while also gaining Fast Track development status for the Elacestrant oncology program.
Prior to joining Radius, Mr. Ward held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 2016 where he chairs the Governance Committee. He served as a Director of Radius from December 2013 until July 2017. Mr. Ward serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the Johns Hopkins University School of Medicine.